Type I

Insulin-Pramlintide Injection Shows Benefit for Type 1

Pramlintide is an FDA-approved medication that is used in combination with insulin therapy for adults with type 1 diabetes and type 2 diabetes. It is a synthetic analog of amylin, a hormone that works alongside insulin to regulate blood sugar levels. The combination of insulin and pramlintide in a single injection has been shown to […]

Adding a Second Medication to Artificial Pancreas Systems

In people who do not have diabetes, the hormone amylin is secreted in the pancreas alongside insulin, and people with diabetes lack both insulin and amylin. Do artificial pancreas systems perform more effectively when pramlintide, a medication that is an analog of amylin, is added to them? Read more

Bridging the Gap Between Youth and Adult Type 1 Diabetes Care

Transitioning from pediatric to adult-oriented care for type 1 diabetes is challenging for many young patients. Researchers found that adolescents with type 1 diabetes who visited with a certified diabetes educator or used a continuous glucose monitor (CGM) before transferring to adult care experienced a shorter gap in care, and potentially a reduced risk of […]

FDA Approves First “Artificial Intelligence” Insulin Pen Cap

The FDA has cleared The Bigfoot Unity AI Diabetes Management System by Bigfoot Biomedical, an artificially intelligent insulin pen cap, for use in type 1 and type 2 diabetes patients aged 12 or older. The device has the potential to make insulin dosing much less burdensome for many patients. Read more

A Potential Type 1 Vaccine Shows Promise

Researchers have devised a new potential type 1 diabetes vaccine that might be able to stop or slow the destruction of insulin-producing beta cells. The Swedish researcher developed a vaccine made from glutamic acid decarboxylase (GAD), a protein anchored to the surface of beta cells that many people with type 1 diabetes form antibodies against. […]

FDA Gives Go-Ahead to Type 1 Drug in Development

Provention Bio has announced that the FDA’s advisory committee voted 10-7 that the benefits outweigh the risks of their drug candidate teplizumab, which is designed to delay the development of type 1 diabetes. The committee based its decision on safety and efficacy data from TN-10 Study in which a single 14-day course of teplizumab delayed […]

Early Life Antibiotic Treatment May Increase Type 1 Risk

Exposure to antibiotic treatment, both prenatal and in the first year of a child’s life, may increase the risk of developing type 1 diabetes before the age of ten, a Swedish study has found. A possible cause is that antibiotics can create alterations in the gut microbiome composition, and subsequently affect the immune system’s development. […]

Nearly 1 in 5 Americans with Diabetes Missed Medical Appointments Due to Pandemic Fears

The COVID-19 pandemic has made managing their diabetes more difficult for many Americans, new research says. 19% of Americans with diabetes skipped at least one medical appointment due to fear of contracting the virus. Almost a quarter say that managing their diabetes has been difficult due to the pandemic, while 17% say they have developed […]

Genetic Mapping May Help Predict Type 1 Diabetes

Researchers at University of California San Diego School of Medicine say they have identified specific cell types that can contribute to causing type 1 diabetes. The researchers made their findings through mapping details of how and when genes are turned on and off in cells, which affects production of proteins needed for specific cellular functions. […]

Barriers to Adapting Type 1 Diabetes Tech

Advances in diabetes technology, like CGMs and automated insulin delivery systems, are associated with improved outcomes for people with diabetes. However, some people have been less likely to make use of these technologies, possibly due to factors of cost, socioeconomic background, or racial disparities. A large study examines the barriers to using diabetes tech. Read […]

A New Oral Type 1 Diabetes Drug

TTP399 is a potential new oral medication to lower and stabilize blood glucose in people with type 1 diabetes (T1D). If approved, TTP399 will be the first oral pill to treat T1D. In conjunction with insulin TTP399 should lower blood glucose without raising the risk of either diabetic ketoacidosis (DKA) or low blood glucose. Diabetes […]

Metabolic Syndrome and the Risk for Type 1 Diabetes Complications

Metabolic syndrome encompasses several cardiovascular risk factors, including abdominal obesity, dyslipidemia, hypertension, insulin resistance, and prothrombic and proinflammatory states. Metabolic syndrome has long been associated with type 2 diabetes and insulin resistance; however, with rising obesity rates, an association between metabolic syndrome and type 1 diabetes has also developed. Read more

Improving Care for Young Black & Hispanic Type 1 Patients

Healthcare providers need to do more to bring young Black and Hispanic patients with type 1 diabetes into a shared decision-making process, a recent study says. Improving shared decision-making could help reduce racial-ethnic inequity in use of diabetes technology. Read more

COVID-19 Increased DKA Rate in Children with Type 1

A study in Germany found that children with a new diagnosis of type 1 diabetes experienced higher rates of diabetic ketoacidosis (DKA), a dangerous complication of diabetes, during the COVID-19 pandemic. Read more

Insulin Dosing Before Exercise

Exercise is essential for people with diabetes, but it also can contribute to variations in blood sugar levels, depending on the type of exercise, duration, and many other factors. A small pilot study suggests that low insulin with modest hyperglycemia may be better than higher insulin levels when exercising with type 1 diabetes. Read more

FDA Gives Breakthrough Designation to Type 1 Drug

The U.S. Food and Drug Administration (FDA) grants its Breakthrough Therapy designation to new drugs that show promise, to speed up the drugs’ development and review. A new type 1 diabetes drug, vTv Therapeutics’ TTP399, which is being developed as an adjunctive therapy to insulin for type 1 diabetes, has been granted this designation. Read […]

Is There a Link Between having Type 1 and Being Transgender?

Studies suggest that rates of type 1 diabetes are higher among people who are transgender or gender diverse than among the general population. Read more

Will Gene Therapy Transform Diabetes Treatment?

Gene therapy has so far been explored mainly in the treatment of rare diseases, but researchers are now turning to how it may be used to treat type 1 diabetes. Gene therapy advocates say the research could transform type 1 treatment, but the research is in its early stages and many obstacles need to be […]

Sotagliflozin + Insulin for Type 1 Diabetes

SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more

Could COVID-19 Increase Risk for Type 1 Diabetes?

Researchers have found that certain viral infections may increase the incidence of type 1 diabetes, and are now investigating whether COVID-19 is among them. Learning more about how viruses may lead to diabetes could help develop strategies for prevention. Read more